Brain implant company Synchron has halted clinical trials of its second-generation device after it failed to perform as expected in initial study participants, according to Wired. The Brooklyn-based startup paused patient enrollment this spring following problems with the cable that carries signals from the implant.
Key takeaways
- Synchron stopped trials of its newer brain device after discovering performance snags.
- The company stated the trouble lies in the lead cable, not the mesh tube itself.
- No safety risks have been linked to the implant so far.
- Synchron is now bringing lead design and manufacturing inside the company.
Why did synchron clinical trials get paused?
Sources familiar with the studies told Wired that trial sites in the US, Australia, and Canada halted patient enrollment because the newer hardware fell short of expectations. Synchron stated that it chose to pause the work voluntarily rather than waiting for an order from regulators at the FDA.
The issue centers on the lead, which acts as the cable carrying signals from the stent-like mesh tube to the implanted electronics. Executives noted that the main mesh tube itself is not the source of the trouble, and officials found no safety hazards tied to the hardware.
What is next for the Stentrode device?
Instead of merely patching the existing cable, the firm is upgrading the entire system. Workers are building up a team in San Diego to support this hardware overhaul, while shrinking operations in New York and cutting jobs as part of a broader corporate restructuring.
The startup develops a wireless brain computer interface designed to let users direct digital tools via thought alone. Ten earlier volunteers received the first-generation system, which relied on an external wire, and used it to send text messages, shop online, and manage banking tasks.
What this means for the company and patients
Patients awaiting the newer wireless hardware must wait while engineers redesign the system components. Synchron plans to restart enrollment once the hardware upgrades finish. Meanwhile, the enterprise continues competing in the broader neural tech sector against rivals like Elon Musk’s Neuralink.
Frequently asked questions
Synchron halted its clinical studies voluntarily after spotting a performance snag with the cable that carries signals from the implant to the internal electronics.
No, the halt was entirely a company choice rather than an official action ordered by the Food and Drug Administration.
Officials stated that no safety hazards associated with the implant have been identified during the evaluation process.
The stent-like mesh tube is guided through the jugular vein to sit atop the brain motor cortex, allowing users to control digital tools via thoughts.
The startup is cutting jobs, scaling back its footprint in New York, and building a team in San Diego while bringing lead design in-house.
Based on reporting by Wired. Read the original article
